NCT05318157

Efficacy of Artemisia Pollen Specific Allergen Immunotherapy

Long Term Efficacy of Artemisia Pollen Specific Allergen Immunotherapy in Patients With Seasonal Allergic Rhinitis

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Beijing Tongren Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Allergic rhinitis (AR) is a noninfectious inflammatory disease of the nasal mucosa mediated by immunoglobulin E (IgE) after exposure to allergens. Artemisia annua is one of the most important allergen that is responsible for seasonal AR in China during July and October. Allergen specific immunotherapy (AIT) is the only etiological treatment available for AR. The trial is a randomized, Open label, multicentred trial. A total of 150 subjects with allergic rhinitis caused by Artemisia pollen were recruited and randomized to the immunotherapy group and conversation drugs group.

Conditions

• Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	AIT drops	Once a day
DRUG	Clarityne, Rhinocort and Emedastine Difumarate Eye Drops	The following drugs were permitted as allergy symptoms-relieving medications according to the actual needs in groups: Clarityne, Rhinocort and Emedastine Difumarate Eye Drops, Once a day

Timeline

• Start date: 2022-03-31
• Primary completion: 2024-10-15
• Completion: 2024-11-30
• First posted: 2022-04-08
• Last updated: 2022-05-26

Locations

3 sites across 1 country: China